Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study

Table 2 Laboratory Values at Baseline and change from Baseline at Weeks 12 and 16 of Lanthanum Carbonate Treatment (ITT Population)

Assessment	Corrected Serum Ca, mg/dL	Ca × P Product, mg²/dL²	Biointact PTH, pg/mL
Baseline	9.49 ± 0.06	56.16 ± 0.49	241.88 ± 7.15
LC change from baseline to week 12	−0.13 ± 0.06*	−1.15 ± 0.62	59.19 ± 7.33*
LC change from baseline week 16	−0.09 ± 0.06	−0.30 ± 0.66	49.30 ± 7.70*

Ca = calcium; Ca × P = calcium × phosphorus; ITT = intent to treat; LC = lanthanum carbonate; PTH = parathyroid hormone.
All data are mean ± standard error of the mean. *P≤ 0.05.

ISSN: 1471-2369